A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)

Status: Open to Accrual

Learn more:

• clinicaltrials.gov: #NCT04849364

Study Contact: studies@hoosiercancer.org; (317) 921-2050.